{
  "ticker": "ILA",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02959023",
  "id": "02959023",
  "pages": 26,
  "price_sensitive": false,
  "date": "20250617",
  "time": "0846",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250617/pdf/06kt859kjs14j5.pdf",
  "summary": "### Key Material Information (Clinical Trial Results Announcement):  \n\n- **Positive Phase 2a/b PROTECT Trial Results** for ISLA-101 in dengue:  \n  - **Preventative cohort**: Significant reduction in viremia (viral load) and symptoms.  \n  - **Treatment cohort**: Signals of drug effect observed, with reduced viremia duration in both cohorts.  \n  - **First molecule** to show potential benefit in the SUNY Dengue Human Infection Model.  \n\n- **Regulatory Pathway**:  \n  - Potential **Priority Review Voucher (PRV)** from FDA (estimated value ~A$225M) if approved.  \n  - Ongoing engagement with FDA and strategic partners for Phase 2b/3 trials.  \n\n- **Next Steps**:  \n  - Further analysis of Phase 2 data to finalize clinical trial design (preventative and/or therapeutic pathways).  \n  - Webinar scheduled for **17 June 2025** (11:00 AM AEST) to discuss results and strategy.  \n\n- **Market Opportunity**:  \n  - Global dengue treatment market projected to reach **~US$3.67B by 2035**; no approved small-molecule therapy currently exists.  \n\n*Note: No financial or capital-raising updates provided in this announcement.*",
  "usage": {
    "prompt_tokens": 6130,
    "completion_tokens": 267,
    "total_tokens": 6397,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-06-16T23:01:10.697908"
}